Todos Medical’s Antiviral Treatment Tollovir Reduces COVID-19 Mortality in Observational Trial

Todos Medical’s Antiviral Treatment Tollovir Reduces COVID-19 Mortality in Observational Trial

Todos Medical announced results from an observational study of 32 hospitalized COVID-19 patients treated with Tollovir, the Company’s proprietary oral antiviral 3CL protease inhibitor treatment. The study compared 11 patients treated with Tollovir to 21 randomly selected untreated patients in the hospitalized setting. Patients treated with Tolliver experienced a reduction in a key inflammatory biomarker, C-reactive protein (CRP).  Tolliver also resulted in a reduction in time of hospitalization and death rate with no deaths recorded in treatment group. All clinical results were collected by the Company’s joint venture partner NLC Pharma in Israel. Dr. Ilan G. Ron, Clinical Professor of Oncology and Radiotherapy at Tel Aviv Medical Center Faculty & Medicine served as the Principal Investigator for the observational study.

Zero deaths were reported in the treated cohort versus 5 deaths in the observational group, which represented a 23% mortality rate in that population.  At baseline the hospitalized patients were evaluated for CRP.  Both the treated and observational group had similarly high levels, but 50% of the treated group experienced an over 50% reduction in ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee